-
Jan 2022
Guidelines for standardizing T-cell cytometry assays to link biomarkers, mechanisms, and disease outcomes in type 1 diabetes.
Eur J ImmunolYang JHM, Ward-Hartstonge KA, Perry DJ, Blanchfield JL, Posgai AL, Wiedeman AE, Diggins K, Rahman A, Tree TIM, Brusko TM, Levings MK, James EA, Kent SC, Speake C, Homann D, Long SA, Immunology of Diabetes Society T-Cell Cytometry Group. -
Jan 2022
Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity.
Sci Transl MedLambert K, Moo KG, Arnett A, Goel G, Hu A, Flynn KJ, Speake C, Wiedeman AE, Gersuk VH, Linsley PS, Greenbaum CJ, Long SA, Partridge R, Buckner JH, Khor B -
Nov 2021
A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetes.
Immunother AdvMarwaha AK, Chow S, Pesenacker AM, Cook L, Sun A, Long SA, Yang JHM, Ward-Hartstonge KA, Williams E, Domingo-Vila C, Halani K, Harris KM, Tree TIM, Levings MK, Elliott T, Tan R, Dutz JP -
Nov 2021
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.
JCI InsightGreenbaum CJ, Serti E, Lambert K, Weiner LJ, Kanaparthi S, Lord S, Gitelman SE, Wilson DM, Gaglia JL, Griffin KJ, Russell WE, Raskin P, Moran A, Willi SM, Tsalikian E, DiMeglio LA, Herold KC, Moore WV, Goland R, Harris M, Craig ME, Schatz DA, Baidal DA, Rodriguez H, Utzschneider KM, Nel HJ, Soppe CL, Boyle KD, Cerosaletti K, Keyes-Elstein L, Long SA, Thomas R, McNamara JG, Buckner JH, Sanda S, ITN058AI EXTEND Study Team. -
Aug 2021
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Diabetes EndocrinolGitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA, Gleevec Trial Study Group. -
May 2021
The many faces of islet antigen-specific CD8 T cells: clues to clinical outcome in type 1 diabetes.
Immunol Cell BiolWiedeman AE, Speake C, Long SA -
Apr 2021
Combination therapy in recent-onset type 1 diabetes.
Lancet Diabetes EndocrinolLong SA, Speake C -
Mar 2021
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.
Sci Transl MedSims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, Geyer SM, Moran A, Greenbaum CJ, Evans-Molina C, Herold KC, Type 1 Diabetes TrialNet Study Group. -
Feb 2021
Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects.
JCI InsightDiggins KE, Serti E, Muir V, Rosasco M, Lu T, Balmas E, Nepom GT, Long SA, Linsley PS -
Feb 2021
The COVID-19 immune landscape is dynamically and reversibly correlated with disease severity.
J Clin InvestBolouri H, Speake C, Skibinski D, Long SA, Hocking AM, Campbell DJ, Hamerman JA, Malhotra U, Buckner JH, Benaroya Research Institute COVID-19 Research Team. -
Jan 2021
Weekly injection of IL-2 using an injectable hydrogel reduces autoimmune diabetes incidence in NOD mice.
DiabetologiaNagy N, Kaber G, Kratochvil MJ, Kuipers HF, Ruppert SM, Yadava K, Yang J, Heilshorn SC, Long SA, Pugliese A, Bollyky PL -
Oct 2020
A distinct GM-CSF+ T helper cell subset requires T-bet to adopt a TH1 phenotype and promote neuroinflammation.
Sci ImmunolRasouli J, Casella G, Yoshimura S, Zhang W, Xiao D, Garifallou J, Gonzalez MV, Wiedeman A, Kus A, Mari ER, Fortina P, Hakonarson H, Long SA, Zhang GX, Ciric B, Rostami A -
Jan 2020
Autoreactive CD8+ T cell exhaustion distinguishes subjects with slow type 1 diabetes progression.
J Clin InvestWiedeman AE, Muir VS, Rosasco MG, DeBerg HA, Presnell S, Haas B, Dufort MJ, Speake C, Greenbaum CJ, Serti E, Nepom GT, Blahnik G, Kus AM, James EA, Linsley PS, Long SA -
Jan 2020
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.
Diabetes CareBattaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, Knip M, Jacobsen L, Krischer JP, Long SA, Lundgren M, McKinney EF, Morgan NG, Oram RA, Pastinen T, Peters MC, Petrelli A, Qian X, Redondo MJ, Roep BO, Schatz D, Skibinski D, Peakman M -
Dec 2019
Efficient CRISPR/Cas9 Disruption of Autoimmune-Associated Genes Reveals Key Signaling Programs in Primary Human T Cells.
J ImmunolAnderson W, Thorpe J, Long SA, Rawlings DJ
